Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.

Müller HL, Merks JHM, Geoerger B, Grill J, Hargrave D, Glade Bender J, Gururangan S, Navid F, Johnston M, Bachir J, Elze MC, Fürst-Recktenwald S.

Pediatr Blood Cancer. 2018 Oct 30:e27487. doi: 10.1002/pbc.27487. [Epub ahead of print]

PMID:
30378286
2.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G.

Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.

PMID:
29936064
3.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

4.

Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.

Marks LJ, Oberg JA, Pendrick D, Sireci AN, Glasser C, Coval C, Zylber RJ, Chung WK, Pang J, Turk AT, Hsiao SJ, Mansukhani MM, Glade Bender JL, Kung AL, Sulis ML.

Front Pediatr. 2017 Dec 12;5:265. doi: 10.3389/fped.2017.00265. eCollection 2017.

5.

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH.

Mod Pathol. 2018 Mar;31(3):463-473. doi: 10.1038/modpathol.2017.127. Epub 2017 Nov 3.

PMID:
29099503
6.

Emerging and investigational therapies for neuroblastoma.

Applebaum MA, Desai AV, Glade Bender JL, Cohn SL.

Expert Opin Orphan Drugs. 2017;5(4):355-368. doi: 10.1080/21678707.2017.1304212. Epub 2017 Mar 17.

7.

Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.

Glasser CL, Lee A, Eslin D, Marks L, Modak S, Glade Bender JL.

J Pediatr Hematol Oncol. 2017 Oct;39(7):560-564. doi: 10.1097/MPH.0000000000000868.

8.

Clinical trial enrollment of adolescents and young adults with sarcoma.

Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL.

Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11. Review.

9.

Pediatric oncology enters an era of precision medicine.

Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW.

Curr Probl Cancer. 2017 May - Jun;41(3):194-200. doi: 10.1016/j.currproblcancer.2017.01.002. Epub 2017 Feb 1.

PMID:
28343740
10.

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.

Hsiao SJ, Karajannis MA, Diolaiti D, Mansukhani MM, Bender JG, Kung AL, Garvin JH Jr.

Cold Spring Harb Mol Case Stud. 2017 Mar;3(2):a001396. doi: 10.1101/mcs.a001396.

11.

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.

12.

Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

Sands S, Ladas EJ, Kelly KM, Weiner M, Lin M, Ndao DH, Dave A, Vahdat LT, Bender JG.

Support Care Cancer. 2017 Mar;25(3):701-708. doi: 10.1007/s00520-016-3441-6. Epub 2016 Nov 9.

13.

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.

Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL.

Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0.

14.

Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience.

Marron JM, DuBois SG, Glade Bender J, Kim A, Crompton BD, Meyer SC, Janeway KA, Mack JW.

Pediatr Blood Cancer. 2016 Nov;63(11):1974-82. doi: 10.1002/pbc.26137. Epub 2016 Jul 18.

15.

Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy.

Kuo DJ, Menell JS, Glade Bender JL.

J Pediatr Hematol Oncol. 2016 Jul;38(5):e169-72. doi: 10.1097/MPH.0000000000000571.

PMID:
27164526
16.

Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.

Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000471. doi: 10.1101/mcs.a000471.

17.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA.

JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print]

PMID:
26822149
18.

Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research.

Oberg JA, Glade Bender JL, Cohn EG, Morris M, Ruiz J, Chung WK, Appelbaum PS, Kung AL, Levine JM.

Pediatr Blood Cancer. 2015 Aug;62(8):1374-80. doi: 10.1002/pbc.25520. Epub 2015 Apr 1.

PMID:
25832998
19.

Translating genomic discoveries to the clinic in pediatric oncology.

Glade Bender J, Verma A, Schiffman JD.

Curr Opin Pediatr. 2015 Feb;27(1):34-43. doi: 10.1097/MOP.0000000000000172. Review.

PMID:
25502895
20.

Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B.

Pediatr Blood Cancer. 2015 Jan;62(1):45-51. doi: 10.1002/pbc.25229. Epub 2014 Sep 24.

Supplemental Content

Loading ...
Support Center